LANSING, Mich., March 4, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”), the leading developer of advanced spider silk based fibers, announced today that the silkworm hatchlings from the first stage of its Monster Silk™ pilot production program (“program”) have now spun cocoons. The cocoons are made of Monster Silk™, the Company’s recombinant spider silk.

The program is running in three stages, with stage 1 being the first of the production stages to produce Monster Silk™ cocoons. Stage 2 of the program is now entering a very advanced state. All three stages are ahead of schedule and are hitting or exceeding their milestones.

“Our focus on innovation and scientific excellence is transitioning well from the laboratory to production, and this ambitious pilot production program is designed to test our systems and to become the basis for large commercial scale production,” said Company founder and CEO, Kim K. Thompson.

“The pilot production program goals included confirming Monster Silk’s™ production scalability; to get these results so smoothly is a tremendous boost the Company’s expansion plans.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Phase Three Launches on the Heels of the Early Successes of Stages One and Two

LANSING, Mich., Feb. 28, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”), the leading developer of advanced spider silk based fiber technologies, announced today the launch of stage 3 of its pilot production program (“program”).

The program is designed to run in three stages, each launching in turn when the data from the previous stage indicates that the program is reaching its benchmarks.

“The launch of stage three indicates stages 1 and 2 are exceeding our expectations with hatch rates exceeding 60%. At the current rates of the program’s development, we should be able to announce that hatchlings from the first round have begun spinning Monster Silk™ within the next few days,” said Company founder and CEO, Kim K. Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., Feb. 25, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”), the leading developer of advanced spider silk based fiber technologies, announced today that the first two stages of its Monster Silk™ pilot production program (“program”) are running ahead of schedule and that both stages of the program are on track to meet or exceed the program’s goals.

The production capacity for the first two stages exceeds the Company’s prior maximum capacities by a factor of four or five.

The program is designed to be the basis of the Company’s large scale commercial production of its recombinant spider silks. The program is designed to run in three stages; with each successive stage launching when the previous stage’s data indicates that the program is reaching, or exceeding, its benchmarks.

The current data supports the continued fast-tracking of the program, as the second phase is developing on track, surpassing the trial’s initial phase in terms of capacity and success rates. The first stage continues to run ahead of expectations and is already moving to an advanced state.

“So far the pilot production program has exceeded our expectations and is confirming that our production model is fully scalable, as Phase II surpassed the program’s first phase, despite the fact that it’s a much larger trial,” said Kraig founder and CEO, Kim Thompson. “From the beginning, this has been an ambitious program, which now appears to be rewarding our efforts. We are continuing to rapidly advance through stage two of the production program.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. The Company has recently launched a pilot production program as a major step toward large scale commercial production.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., Feb. 19, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Kraig” or “The Company”) announces an advance conference call advisory for all shareholders and other interested parties.

The Company plans to host a conference call for the purpose of discussing production, commercialization and scientific milestones as well as other corporate developments, featuring the Kraig’s founder and CEO, Kim Thompson and is tentatively scheduled for late-March to mid-April, pending the travel schedule of Thompson and members of the scientific team.

Kraig recently announced that it signed a memorandum of understanding with SSM Industries Inc. (www.Ssmind.com) to jointly commercialize Kraig’s Monster Silk(TM) recombinant spider silk. Other recent announcements included that the Company launched and is accelerating its Monster Silk(TM) pilot production program, as well as that it succeeded in creating “Big Red”, a new type of recombinant spider silk.

The Company plans on releasing definitive details, including call-in details, time and format, at least one week prior to conference call and shareholders are invited to submit questions to ir@kraiglabs.com.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@kraiglabs.com

LANSING, MI, Feb. 13, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig”) and SSM Industries, Inc. (“SSM”) jointly announced today that they have signed a memorandum of understanding (“MOU”) to jointly commercialize Kraig’s Monster Silk™ recombinant spider silk.

The purpose of the MOU is to develop a framework for cooperation between SSM and Kraig regarding spider silk commercialization and marketing. The parties anticipate collaborating to develop knitted and woven textiles utilizing Monster Silk™ and possibly other recombinant spider silks, which have been developed by Kraig or which are in its development pipeline.

The collaborative work would extend to product applications’ development and marketing. Under the MOU the two companies would jointly develop select applications, for Monster Silk™ and other recombinant spider silks which have been developed by Kraig. This alliance is intended to support the market development for spider silk based textiles.

“SSM Industries, Inc. is an American company with a proven track record of innovation and excellence in technical textiles and protective apparel, so we are delighted to be working with them,” said Kraig CEO and founder, Kim Thompson. “Today’s memorandum of understanding allows us to work toward combining the capabilities of both companies in pursuing markets for knitted and woven applications of spider silk.

“This MOU is a big step forward in moving our spider silk products from the laboratory and toward meeting the increasing demand for innovative high strength materials, technical textiles and protective composites. I believe that it greatly accelerates Kraig’s access to critical protective clothing and technical markets.

“This collaboration with a technical textile innovator marks a major milestone toward bringing Kraig Biocraft Laboratories’ genetically engineered spider silks to mainstream markets in commercial volume,” concluded Thompson.

“We are very happy to enter into co-operation between Kraig Labs and SSM Industries for developing the markets and product applications for spider silks, especially in regard to life & limb protective gear, apparel and composites,” said SSM spokesman Phil Chandler.

“Both parties acknowledge the potential of working together to develop and promote recombinant spider silk related textiles and product applications,” continued Mr. Chandler. “I believe the signing of the MOU between our companies marks a starting point for the development of significant markets for spider silk technologies. We are excited to be at the ground floor as we work together with Kraig to develop and grow this market segment. This new relationship demonstrates SSM Industries commitment to unlocking markets and developing innovative solutions that benefit our world and satisfy global demand.”

The parties caution that while the MOU is a major step toward a binding agreement, it should not be relied upon as a guarantee that a binding agreement will be completed.

Kraig Biocraft Laboratories is in discussions with other companies to complete a consortium to drive the penetration of its recombinant spider silks into global markets.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

About SSM Industries

SSM Industries Inc. (www.Ssmind.com), based in Spring City, TN, is a full service safety and protective fabric manufacturer that manufactures flame resistant, cut resistant, and thermal fabrics.

SSM has established itself as an innovator in technical textiles and performs in-house yarn spinning, knitting, weaving, dyeing and finishing. The company produces products that are used by the U.S. military, the auto racing industry, firefighters, first responders, and industrial applications where materials with strength and protective properties are required. Internal research and development and an in-house Military certified lab to test the finished fabrics complement SSM’s vast technical textile capabilities.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@kraiglabs.com

LANSING, Mich., Feb. 4, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (KBLB) (the “Company” or “Kraig”) announced today that it is accelerating its pilot production program, as a result of positive initial data from the first stage of the trial.

The acceleration to the second phase of the program is designed to increase production capacity of Monster Silk™, the Company’s recombinant spider silk, by more than tenfold over the first stage. Kraig’s strategy calls on further accelerating the production program by initiating a third stage, if the program continues to meet its targets.

The first phase of the pilot production program for Monster Silk™ is continuing, even as phase two is being launched. The purpose of the program is to verify scalability and favorable production economics of Monster Silk™, to significantly increase production, and to form the basis of large scale commercial production of the Company’s recombinant spider silks.

“The initial success of the first stage has given us the confidence to accelerate the program,” said Kraig founder and CEO, Kim Thompson. “We are now well ahead of the schedule that we envisioned even a few weeks ago. This is a critical step forward in the commercializing of our laboratory discoveries. The launching of stage two, which I view as the heart of the pilot production program, is the most exciting and momentous event in the Company’s history, second only to our invention of Monster Silk™.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com

Photos of Big Red, Kraig’s Recently Developed Recombinant Spider Silk Which is Designed for Increased Strength

LANSING, Mich., Jan. 28, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”) announced today that World Textile Information Network (“WTiN”) recently published an article, entitled “Commercializing the science of spider silk”, featuring the Company and its genetically engineered spider silk technologies.

As the WTiN article states, “Kraig Biocraft Laboratories has experienced growing success developing its recombinant spider silk in the last two years.” The article describes Kraig’s product development and includes the first published photos of the Company’s new composite spider silk fiber, “Big Red.” The new genetically engineered spider silk fiber takes its name from the fact that it glows bright red under UV illumination. Additional photos of what the Company hopes to be a breakthrough material will be posted on Kraig’s website.

The WTiN article is available at the following link: http://ei.wtin.com/article/fQowSDlzdX2/2013/01/24/commercialising_the_science_of_spider_silk/.

World Textile Information Network, established more than 100 years ago and based in the UK, is the world’s leading textile news and information provider, with unrivalled textile expertise. “WTiN Intelligence” is part of the WTiN, whose magazines include- Textile Month International, Knitting International, Future Materials, Nonwovens Report International, Digital Textile, Twist and International Dyer, as well as newspapers at many of the world’s leading textile exhibitions.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:
Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com

LANSING, Mich., Jan. 22, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”) announced today that it plans on launching its pilot production program for Monster Silk™, the Company’s recombinant spider silk, in the first or second quarter of 2013.

The program is designed to transition Kraig from laboratory scale production to commercial. scale production of Monster Silk™. The Company anticipates launching the pilot program within the next sixty to ninety days. The initial goals for the pilot production program are to confirm production scalability and cost structures for Monster Silk™, as well as to satisfy the demand for larger scale Monster Silk™ sample requests from textile producers and product developers.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com

LANSING, Mich., Jan. 14, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”) announced that researchers, working pursuant to Kraig’s collaborative research program, utilizing customized spider silk genetic engineering sequences, succeeded in creating a new type of recombinant spider silk, which the Company is designating as “Big Red.”

The “Big Red” silk is currently being spun within the laboratory by transgenicly modified silkworms.

“‘Big Red’ is a composite fiber,” said Company CEO, Kim Thompson. “This new type of fiber was designed to be a combination of spider silk proteins, silkworm silk proteins and protein from an unrelated species. From a genetic perspective, what significantly differentiates this material from our Monster Silk™ is the unique spider silk genetic sequence that we used, which we designed to increase strength to weight ratios. Another important difference is the incorporation of a unique protein, which gives the new fiber its designation as ‘red.’

“The design for ‘Big Red’ derived from what we learned about the mechanical characteristics of recombinant spider silk fibers from our work with Monster Silk™,” continued Thompson. “Specifically, the new fiber was designed to place more emphasis on tensile strength and slightly less emphasis on elongation. We anticipate that ‘Big Red’ will be a powerful arrow in our quiver as we move to commercialize Monster Silk™ and the Company is hopeful that this new material will follow it in the commercialization pipeline. In my view, the creation of Big Red demonstrates the power of our technology to continue to develop new and exciting materials.”

The “Big Red” name comes in part from the fact that the fibers have a slight red cast. Under UV light, the new fibers actually glow bright red.

Thompson further stated, “The successful creation of these new materials once again validates our scientific models. Based upon the observed levels of color expression and the nature of the spider silk genetic configurations used in its creation, the hope is that it will find its own significant niche in the technical textiles marketplace. Preparation for mechanical testing of the new fiber is currently taking place.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

CONTACT:

Ben Hansel
(720) 288-8495
benhansel@yahoo.com